The role of decitabine in the treatment of myelodysplastic syndromes

Bibliography

• GERMING U, STRUPP C, KUNDGEN A et al.: No increase in age-specific incidence of myelodysplastic syndromes. Haematologica (2004) 89:905-910.
   PubMed Web of Science ®Google Scholar
• GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088.
   PubMed Web of Science ®Google Scholar
• BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. (1982) 51:189-199.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November 1997. J. Clin. Oncol. (1999) 17:3835-3849.
   PubMed Web of Science ®Google Scholar
• ATALLAH E, UBERTI J, AYASH L, BENTLEY G, VANDAHM J, RATANATHARATHORN V: Fifteen-year follow up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan-based regimens. ASH Annual Meeting Abstracts. Blood (2005) 106:5461.
   Google Scholar
• CUTLER CS, LEE SJ, GREENBERG P et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood (2004) 104:579-585.
   PubMed Web of Science ®Google Scholar
• JADERSTEN M, MONTGOMERY SM, DYBEDAL I, PORWIT-MACDONALD A, HELLSTROM-LINDBERG E: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood (2005) 106:803-811.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, BERAN M, CORTES J et al.: Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer (2006) 106:1099-1109.
   PubMed Web of Science ®Google Scholar
• MOLLDREM JJ, LEIFER E, BAHCECI E et al.: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. (2002) 137:156-163.
   PubMed Web of Science ®Google Scholar
• YAZJI S, GILES FJ, TSIMBERIDOU AM et al.: Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia (2003) 17:2101-2106.
   PubMed Web of Science ®Google Scholar
• BOUSCARY D, LEGROS L, TULLIEZ M et al.: A non-randomised dose-escalating Phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br. J. Haematol. (2005) 131:609-618.
   PubMed Web of Science ®Google Scholar
• LIST A, KURTIN S, ROE DJ et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. (2005) 352:549-557.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR, DEMAKOS EP, PETERSON BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. (2002) 20:2429-2440.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, ISSA JP, ROSENFELD CS et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer (2006) 106:1794-1803.
   PubMed Web of Science ®Google Scholar
• LIST AF, DEWALD G, BENNETT J et al.: Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31. 1 deletion: results of the multicenter MDS-003 Study. ASCO Meeting Abstracts (2005) 23:5.
   Google Scholar
• CHESON BD, BENNETT JM, KANTARJIAN H et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 96:3671-3674.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Response rates using International Working Group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine. ASH Annual Meeting Abstracts. Blood (2005) 106:2526.
   Google Scholar
• SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Analysis of survival, AML transformation, and transfusion independence in patients with high-risk myelodysplastic syndromes (MDS) receiving azacitidine determined using a prognostic model. ASH Annual Meeting Abstracts. Blood (2005) 106:2523.
   Google Scholar
• SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients ≥ 65 years of age. ASH Annual Meeting Abstracts. Blood (2005) 106:2524.
   Google Scholar
• JONES PA, TAYLOR SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 20:85-93.
   PubMed Web of Science ®Google Scholar
• DASKALAKIS M, NGUYEN TT, NGUYEN C et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatment. Blood (2002) 100:2957-2964.
   PubMed Web of Science ®Google Scholar
• UCHIDA T, KINOSHITA T, NAGAI H et al.: Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood (1997) 90:1403-1409.
   PubMed Web of Science ®Google Scholar
• YANG AS, DOSHI KD, CHOI SW et al.: DNA methylation changes after 5-aza-2’-deoxycytidine therapy in patients with leukemia. Cancer Res. (2006) 66:5495-5503.
   PubMed Web of Science ®Google Scholar
• HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. (2003) 349:2042-2054.
   PubMed Web of Science ®Google Scholar
• HERMAN JG: Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. (1999) 9:359-367.
   PubMed Web of Science ®Google Scholar
• BARLOW DP: Gametic imprinting in mammals. Science (1995) 270:1610-1613.
   PubMed Web of Science ®Google Scholar
• GOTO T, MONK M: Regulation of X chromosome inactivation in development in mice and humans. Microbiol. Mol. Biol. Rev. (1998) 62:362-378.
   PubMed Web of Science ®Google Scholar
• SANTINI V, KANTARJIAN HM, ISSA JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. (2001) 134:573-586.
   PubMed Web of Science ®Google Scholar
• SCHMELZ K, WAGNER M, DORKEN B, TAMM I: 5-Aza-2´-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int. J. Cancer (2005) 114:683-695.
   PubMed Web of Science ®Google Scholar
• MUND C, HACKANSON B, STRESEMANN C, LUBBERT M, LYKO F: Characterization of DNA demethylation effects induced by 5-aza-2´-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. (2005) 65:7086-7090.
   PubMed Web of Science ®Google Scholar
• ISSA JP, GARCIA-MANERO G, GILES FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 103:1635-1640.
   PubMed Web of Science ®Google Scholar
• GARCIA-MANERO G, KANTARJIAN HM, SANCHEZ-GONZALEZ B et al.: Phase I/II study of the combination of 5-aza-2´-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 108:3271-3278.
   PubMed Web of Science ®Google Scholar
• PLIML J, SORM F: Synthesis of 2-deoxy-d-ribofuranosyl-5-azacytosine. Collection of Czechoslovak Chemical Communications (1964) 29:2576-2577.
   Google Scholar
• SORM F, VESELY J: Effect of 5-aza-2´-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma (1968) 15:339-343.
   PubMed Web of Science ®Google Scholar
• MOMPARLER RL: Pharmacology of 5-aza-2´-deoxycytidine (decitabine). Semin. Hematol. (2005) 42:S9-S16.
   PubMed Web of Science ®Google Scholar
• MOMPARLER RL, ROSSI M, BOUCHARD J, VACCARO C, MOMPARLER LF, BARTOLUCCI S: Kinetic interaction of 5-aza-2´-deoxycytidine-5´-monophosphate and its 5´-triphosphate with deoxycytidylate deaminase. Mol. Pharmacol. (1984) 25:436-440.
   PubMed Web of Science ®Google Scholar
• JUTTERMANN R, LI E, JAENISCH R: Toxicity of 5-aza-2´-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA (1994) 91:11797-11801.
   PubMed Web of Science ®Google Scholar
• APARICIO A, EADS CA, LEONG LA et al.: Phase I trial of continuous infusion 5-aza-2´-deoxycytidine. Cancer Chemother. Pharmacol. (2003) 51:231-239.
   PubMed Web of Science ®Google Scholar
• CASHEN A, SHAH A, HELGET A, TODT L, FISHER N, DIPERSIO J: A Phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). ASH Annual Meeting Abstracts. Blood (2005) 106:1854.
   Google Scholar
• RIVARD GE, MOMPARLER RL, DEMERS J et al.: Phase I study on 5-aza-2´-deoxycytidine in children with acute leukemia. Leuk. Res (1981) 5:453-462.
   PubMed Web of Science ®Google Scholar
• VAN GROENINGEN CJ, LEYVA A, O’BRIEN AM, GALL HE, PINEDO HM: Phase I and pharmacokinetic study of 5-aza-2´-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. (1986) 46:4831-4836.
   PubMed Web of Science ®Google Scholar
• CHABOT GG, BOUCHARD J, MOMPARLER RL: Kinetics of deamination of 5-aza-2´-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem. Pharmacol. (1983) 32:1327-1328.
   PubMed Web of Science ®Google Scholar
• CHABOT GG, RIVARD GE, MOMPARLER RL: Plasma and cerebrospinal fluid pharmacokinetics of 5-aza-2´-deoxycytidine in rabbits and dogs. Cancer Res. (1983) 43:592-597.
   PubMed Web of Science ®Google Scholar
• MOMPARLER RL, BOUFFARD DY, MOMPARLER LF, DIONNE J, BELANGER K, AYOUB J: Pilot Phase I – II study on 5-aza-2´-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs (1997) 8:358-368.
   PubMed Web of Science ®Google Scholar
• SCHWARTSMANN G, SCHUNEMANN H, GORINI CN et al.: A Phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early Phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs (2000) 18:83-91.
   PubMed Web of Science ®Google Scholar
• ZAGONEL V, LO RG, MAROTTA G et al.: 5-Aza-2´-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia (1993) 7(Suppl. 1):30-35.
   PubMed Web of Science ®Google Scholar
• WIJERMANS PW, KRULDER JW, HUIJGENS PC, NEVE P: Continuous infusion of low-dose 5-aza-2´-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia (1997) 11(Suppl. 1):S19-S23.
   PubMed Web of Science ®Google Scholar
• WIJERMANS P, LUBBERT M, VERHOEF G et al.: Low-dose 5-aza-2´-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. (2000) 18:956-962.
   PubMed Web of Science ®Google Scholar
• LUBBERT M, WIJERMANS P, KUNZMANN R et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2´-deoxycytidine. Br. J Haematol. (2001) 114:349-357.
   PubMed Web of Science ®Google Scholar
• VAN DEN BJ, LUBBERT M, VERHOEF G, WIJERMANS PW: The effects of 5-aza-2´-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk. Res. (2004) 28:785-790.
   PubMed Web of Science ®Google Scholar
• RUTER B, WIJERMANS PW, LUBBERT M: Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2´-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer (2006) 106:1744-1750.
   PubMed Web of Science ®Google Scholar
• CHESON BD, GREENBERG PL, BENNETT JM et al.: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 108:419-425
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, OKI Y, GARCIA-MANERO G et al.: Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood In press.
   Google Scholar
• MELKI JR, VINCENT PC, CLARK SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. (1999) 59:3730-3740.
   PubMed Web of Science ®Google Scholar
• TOYOTA M, KOPECKY KJ, TOYOTA MO, JAIR KW, WILLMAN CL, ISSA JP: Methylation profiling in acute myeloid leukemia. Blood (2001) 97:2823-2829.
   PubMed Web of Science ®Google Scholar
• ISSA JP, GHARIBYAN V, CORTES J et al.: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. (2005) 23:3948-3956.
   PubMed Web of Science ®Google Scholar
• ABELE R, CLAVEL M, DODION P et al.: The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2´-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. (1987) 23:1921-1924.
   PubMedGoogle Scholar
• SAMLOWSKI WE, LEACHMAN SA, WADE M et al.: Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol. (2005) 23:3897-3905.
   PubMed Web of Science ®Google Scholar
• GOLLOB JA, SCIAMBI CJ, PETERSON BL et al.: Phase I trial of sequential low-dose 5-aza-2´-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin. Cancer Res. (2006) 12:4619-4627.
   PubMed Web of Science ®Google Scholar
• YANG H, HOSHINO K, SANCHEZ-GONZALEZ B, KANTARJIAN H, GARCIA-MANERO G: Antileukemia activity of the combination of 5-aza-2´-deoxycytidine with valproic acid. Leuk. Res. (2005) 29:739-748.
   PubMed Web of Science ®Google Scholar
• GORE SD, BAYLIN S, SUGAR E et al.: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. (2006) 66:6361-6369.
   PubMed Web of Science ®Google Scholar